Ozempic Thailand

The drug that brought semaglutide to the world

Ozempic was approved by the US FDA in December 2017 for the treatment of type-2 diabetes mellitus. It was the first commercial product of the semaglutide molecule — and the trial program that supported its approval (SUSTAIN 1 through 10) remains the most diverse glycemic-control dataset for any single GLP-1 agent.

The SUSTAIN program was deliberately built to cover a wide range of type-2 diabetes patient archetypes — drug-naive, on metformin, on basal insulin, on SGLT-2 inhibitors, on multiple oral agents. Across all ten trials Ozempic produced consistent HbA1c reductions of 1.0 to 1.8 percentage points and consistent weight loss of 3 to 6 kg as a secondary endpoint.

• SUSTAIN-1 Monotherapy in drug-naive T2D — established baseline efficacy versus placebo.
• SUSTAIN-6 Cardiovascular outcomes trial in T2D — pre-specified non-inferiority met for MACE versus placebo.
• SUSTAIN-7 Head-to-head versus dulaglutide. Aroda and colleagues (Lancet Diabetes Endocrinol 2017) reported superior HbA1c reduction (−1.8% vs −1.4%) and superior weight loss (−6.5 kg vs −3.0 kg) at 40 weeks.
• SUSTAIN-10 Head-to-head versus liraglutide (Victoza/Saxenda's parent). Once-weekly semaglutide produced significantly greater HbA1c and weight reductions than the daily comparator at full dose.

Real-world impact in the 8 years since approval: millions of patients with type-2 diabetes have achieved durable glycemic control with concurrent meaningful weight loss as a secondary effect. It is that secondary effect that drove global demand to exceed manufacturing capacity from 2022 onward.

Off-label weight management with Ozempic in Thailand

Wegovy reaches Thailand in limited supply. When stock is unavailable, Thai endocrinologists routinely prescribe Ozempic off-label to patients seeking weight management — leaning on the fact that the active molecule is identical, only the labelled indication and maximum dose differ.

What the off-label pathway looks like in practice

• 1.Same molecule, same manufacturer. The semaglutide in an Ozempic 1 mg pen and the semaglutide in a Wegovy 1 mg-equivalent pen are bioidentical. There is no chemistry difference.
• 2.Different maximum dose. Ozempic's labelled ceiling is 2 mg weekly. Wegovy goes to 2.4 mg weekly. The difference is small at the receptor level but matters for the patients who need the upper end of the dose curve.
• 3.Most off-label weight patients titrate to 1 mg or 2 mg rather than the 2.4 mg Wegovy maintenance, and report 8 to 12% body-weight reduction over 9 to 12 months — slightly below the published Wegovy figures but well above placebo.
• 4.Pricing parity in Thailand. Per-shot Ozempic and per-shot Wegovy are commonly listed at ฿1,990 in Bangkok clinics. The economic argument for choosing Ozempic over Wegovy is availability, not cost.
• 5.Documentation matters. Off-label use is legal in Thailand under a licensed prescriber. The clinic file should explicitly note the off-label indication, the absence of T2D, and the patient's informed agreement to use a drug outside its registered label.

Why the Ozempic dose ladder differs from Wegovy

Ozempic is supplied in a four-dose pen architecture rather than Wegovy's five-step. The structure reflects its origin as a glycemic-control drug — endocrinologists need finer titration steps when balancing HbA1c, hypoglycaemia risk and weight change simultaneously.

Ozempic or Wegovy — the same molecule, two different choices

Identical drug. Different labelled indication. Different maximum dose. Different supply chain. Here is the short decision matrix Thai endocrinologists use in clinic.

Doctor-led prescription required. Off-label use disclosed and documented where applicable.